TABLE III.

Baseline predictors of clinical asthma remission in male subjects^*†

Clinical phenotype	OR	95% CI	P value
Serum eosinophil count <500 cells/μL	1.79	1.02–3.21	.045
Inhaled budesonide treatment‡	2.05	1.11–3.83	.02
Inhaled nedocromil treatment‡	1.30	0.70–2.42	.41
FEV1/FVC ratio ≥90%§	73.81	13.07–1404.13	<.001
FEV1/FVC ratio 80% to 89%§	25.10	5.16–453.35	.002
FEV1/FVC ratio 70% to 79%§	6.59	1.28–120.93	.07

^*Covariates included in the cross-validated model: age, race, CAMP treatment group, clinic site, household income level, history of wheezing with colds, history of exacerbations after exercise, history of exposure to home tobacco smoke, baseline asthma severity, and serum IgE level.

^†Quantitative variables were modeled categorically.

^‡Reference group is placebo treatment.

^§Reference level is an FEV₁/FVC ratio of less than 70%.